U.S. markets closed

Avid Bioservices, Inc. (CDMOP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
30.86+0.41 (+1.35%)
At close: 3:56PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close30.45
Open30.50
Bid29.60 x 800
Ask31.00 x 4000
Day's Range30.00 - 31.42
52 Week Range17.51 - 31.94
Volume6,283
Avg. Volume4,701
Market Cap252.536M
Beta (5Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-0.08
Earnings DateJun 30, 2020
Forward Dividend & Yield2.62 (8.87%)
Ex-Dividend DateDec 11, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021
    GlobeNewswire

    Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021

    TUSTIN, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2021 on March 8, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the third quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events. To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Avid Bioservices call. About Avid Bioservices, Inc.Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com. CONTACT: Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com

  • Do Institutions Own Avid Bioservices, Inc. (NASDAQ:CDMO) Shares?
    Simply Wall St.

    Do Institutions Own Avid Bioservices, Inc. (NASDAQ:CDMO) Shares?

    A look at the shareholders of Avid Bioservices, Inc. ( NASDAQ:CDMO ) can tell us which group is most powerful. Insiders...

  • Pacira Pharmaceuticals Getting Closer To Key Technical Measure
    Investor's Business Daily

    Pacira Pharmaceuticals Getting Closer To Key Technical Measure

    Pacira Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating